Understanding these differences is especially important if you are switching between medications
doi:10.1002/ana.23865 2GordoisA, ScuffhamP, ShearerA, OglesbyA, TobianJA
Retatrutide itself remains an investigational compound it has not received marketing authorisation from the MHRA in the UK, the European Medicines Agency (EMA), or the US Food and Drug Administration (FDA)
It is especially relevant for patients taking or researching semaglutide, tirzepatide, GLP-1 injections, oral GLP-1 options, or physician-supervised weight loss programs
The result is enhanced healing kinetics, reduced fibrosis, and improved overall tissue resilience 4
Cleveland Clinic also explains that large or prolonged calorie deficits can reduce available energy and affect recovery, due to it being easier for the body to adjust to a smaller calorie deficit than a larger one